Emerging drugs in the treatment of pancreatic cancer (Q37494647)

20 August 2017

1 reference

title

Emerging drugs in the treatment of pancreatic cancer (English)

1 reference

20 August 2017

1 reference

Devalingam Mahalingam

1

1 reference

20 August 2017

Kevin R Kelly

2

1 reference

20 August 2017

Ronan T Swords

3

1 reference

20 August 2017

Jennifer Carew

4

1 reference

20 August 2017

Steffan T Nawrocki

5

1 reference

20 August 2017

Francis J Giles

6

1 reference

20 August 2017

language of work or name

English

0 references

publication date

1 June 2009

1 reference

Expert Opinion on Emerging Drugs

20 August 2017

published in

1 reference

20 August 2017

volume

14

1 reference

20 August 2017

issue

2

1 reference

20 August 2017

page(s)

311-328

1 reference

20 August 2017

cites work

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

New directions in the management of advanced pancreatic cancer: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Genetic progression in the pancreatic ducts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

The molecular genetics of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Molecular advances in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Molecular biology of pancreatic cancer: potential clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Lipid posttranslational modifications. Farnesyl transferase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Understanding Ras: 'it ain't over 'til it's over'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

A raf-independent epidermal growth factor receptor autocrine loop is necessary for Ras transformation of rat intestinal epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Transcriptional regulation and transformation by Myc proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

G protein coupled receptor signaling through the Src and Stat3 pathway: role in proliferation and transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Expression and activity of SRC regulate interleukin-8 expression in pancreatic adenocarcinoma cells: implications for angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

The transcriptional targets of p53 in apoptosis control

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

TGF-beta signaling in tumor suppression and cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Basics of TGF-beta and pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Alterations of cell signaling pathways in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Roles of STAT3 defined by tissue-specific gene targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Aberrant methylation of CpG islands in intraductal papillary mucinous neoplasms of the pancreas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

The Hedgehog signalling pathway and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Activating Smoothened mutations in sporadic basal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Basal cell carcinomas: attack of the hedgehog

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Aberrant methylation of the Human Hedgehog interacting protein (HHIP) gene in pancreatic neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Sonic hedgehog acts at multiple stages during pancreatic tumorigenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

bax, but not bcl-2, influences the prognosis of human pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Disrupting insulin-like growth factor signaling as a potential cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib ('Iressa') response and resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Insulin-like growth factor-I receptor blockade by a specific tyrosine kinase inhibitor for human gastrointestinal carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

The role of hypoxia-inducible factors in tumorigenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Targeted therapy for metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Discovery of a novel Raf kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Upregulation of BNIP3 by 5-aza-2'-deoxycytidine sensitizes pancreatic cancer cells to hypoxia-mediated cell death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Orally administered FTS (salirasib) inhibits human pancreatic tumor growth in nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Farnesyl transferase inhibitor (R115777)-induced inhibition of STAT3(Tyr705) phosphorylation in human pancreatic cancer cell lines require extracellular signal-regulated kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Farnesyl transferase inhibitors: a major breakthrough in anticancer therapy? Naples, 12 April 2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 given as a 1-hour intravenous infusion in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Specific isoprenoid modification is required for function of normal, but not oncogenic, Ras protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Gemcitabine and ISIS-2503 for patients with locally advanced or metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Oncolytic viruses in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

The phosphoinositide 3-kinase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

eIF4E--from translation to transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Prediagnostic plasma folate and the risk of death in patients with colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

The Akt-mTOR tango and its relevance to cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Apo2L/TRAIL and its death and decoy receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Apoptotic pathways: paper wraps stone blunts scissors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Inhibition of prostate cancer proliferation by interference with SONIC HEDGEHOG-GLI1 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Hedgehog signalling in prostate regeneration, neoplasia and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

An orally bioavailable small-molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Pathways of chaperone-mediated protein folding in the cytosol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

HIF-1alpha and STAT3 client proteins interacting with the cancer chaperone Hsp90: therapeutic considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Targeting heat shock protein 90 in pancreatic cancer impairs insulin-like growth factor-I receptor signaling, disrupts an interleukin-6/signal-transducer and activator of transcription 3/hypoxia-inducible factor-1alpha autocrine loop, and reduces or

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Induction of p21WAF1/CIP1 and cyclin D1 expression by the Src oncoprotein in mouse fibroblasts: role of activated STAT3 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Stat3 activation by Src induces specific gene regulation and is required for cell transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Epidermal growth factor receptor-mediated activation of Stat3 during multistage skin carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

STAT3 as a target for inducing apoptosis in solid and hematological tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Abrogation of signal transducer and activator of transcription 3 reactivation after Src kinase inhibition results in synergistic antitumor effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Molecular approaches towards the inhibition of the signal transducer and activator of transcription 3 (Stat3) protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

STAT proteins: novel molecular targets for cancer drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

DNA methylation, methyltransferases, and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Growth delay of human pancreatic cancer cells by methylase inhibitor 5-aza-2'-deoxycytidine treatment is associated with activation of the interferon signalling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Gemcitabine combined with gefitinib in patients with inoperable or metastatic pancreatic cancer: a phase II Study of the Hellenic Cooperative Oncology Group with biomarker evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

Inhibitors of the heat shock response: biology and pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902972502

10.1517/14728210902972502

21 January 2018

Identifiers

DOI

1 reference

20 August 2017

1 reference